ARDELYX INC. - COMMON STOCK

Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8

03 1月 2024 05:03:00 条件 Nasdaq GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

20 12月 2023 05:00:00 条件 Nasdaq GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

21 11月 2023 13:02:00 条件 Nasdaq GlobeNewswire

Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference

21 11月 2023 05:01:45 条件 Nasdaq GlobeNewswire

XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia

15 11月 2023 13:02:00 条件 Nasdaq GlobeNewswire

Ardelyx Announces Departure of Board Member

13 11月 2023 13:02:00 条件 Nasdaq GlobeNewswire

Ardelyx to Participate at the Jefferies London Healthcare Conference

10 11月 2023 05:05:00 条件 Nasdaq GlobeNewswire

Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States

06 11月 2023 05:00:00 条件 Nasdaq GlobeNewswire

Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023

03 11月 2023 05:00:00 条件 Nasdaq GlobeNewswire

Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance

31 10月 2023 04:00:01 条件 Nasdaq GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

30 10月 2023 14:42:57 条件 Nasdaq GlobeNewswire

Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023

23 10月 2023 05:07:01 条件 Nasdaq GlobeNewswire

Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023

18 10月 2023 13:02:39 条件 Nasdaq GlobeNewswire

Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital

17 10月 2023 16:23:38 条件 Nasdaq GlobeNewswire

FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor

17 10月 2023 16:01:06 条件 Nasdaq GlobeNewswire

Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA

13 10月 2023 05:00:00 条件 Nasdaq GlobeNewswire

Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023

04 10月 2023 05:00:00 条件 Nasdaq GlobeNewswire

Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

28 9月 2023 05:02:00 条件 Nasdaq GlobeNewswire

Tenapanor for Hyperphosphatemia Approved in Japan

25 9月 2023 01:15:13 条件 Nasdaq GlobeNewswire

Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023

11 9月 2023 05:00:00 条件 Nasdaq GlobeNewswire